| Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate | Post-Market | Allergic Rhinitis Due to Allergens |
| Placebo | Post-Market | Cystic Fibrosis |
| ATAZANAVIR SULFATE | Approved | |
| FENTANYL | Approved | |
| DEXLANSOPRAZOLE | Approved | |
| METFORMIN HYDROCHLORIDE | Approved | |
| ALPRAZOLAM | Approved | |
| TRIFLUOPERAZINE HYDROCHLORIDE | Approved | |
| THIORIDAZINE HYDROCHLORIDE | Approved | |
| DEXAMETHASONE SODIUM PHOSPHATE | Approved | |
| ACAMPROSATE CALCIUM | Approved | |
| ESTRADIOL | Approved | |
| EPTIFIBATIDE | Approved | |
| Oxybutynin Chloride | Approved | |
| FERRIC CARBOXYMALTOSE | Approved | |
| SUMATRIPTAN SUCCINATE | Approved | |
| ACID REDUCER | Approved | |
| PROMETHAZINE HYDROCHLORIDE | Approved | |
| LENALIDOMIDE | Approved | |
| AMBRISENTAN | Approved | |
| Bevacizumab as MYL-1402O | Phase 3 | NSCLC Stage IV |
| Cenerimod | Phase 3 | Lupus Erythematosus, Systemic |
| Revefenacin | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) |
| Selatogrel | Phase 3 | Acute Myocardial Infarction |
| Transdermal system containing progestin | Phase 3 | Female Contraception |
| MR-100A-01 | Phase 3 | Contraception |
| TD-4208 | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) |
| MYL-1701P, a proposed biosimilar to Eylea | Phase 3 | Diabetic Macular Edema |
| TD-4208 700 μg | Phase 2 | Chronic Obstructive Pulmonary Disease, COPD |
| MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) | Phase 2 | Contraception |
| MR-146 | Phase 1/2 | Neurotrophic Keratopathy |
| Azithromycin Tablets 600 mg | Phase 1 | Healthy |
| Ciprofloxacin Extended-Release Tablets 1000 mg | Phase 1 | Healthy |
| Escitalopram Oxalate Tablets 20 mg | Phase 1 | Healthy |
| Lorazepam Tablets 2 mg | Phase 1 | Healthy |
| Meloxicam Tablets 15 mg | Phase 1 | Healthy |
| Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg | Phase 1 | Healthy |
| Cetirizine HCl Tablets 10 mg | Phase 1 | Healthy |
| Sacubitril and Valsartan Tablets 49mg/51mg | Phase 1 | Bioequivalence Study |
| Pioglitazone HCl Tablets 45 mg | Phase 1 | Healthy |
| Clopidogrel Bisulfate Tablets 75 mg | Phase 1 | Healthy |
| Paroxetine Hydrochloride Controlled-Release Tablets 25 mg | Phase 1 | Healthy |
| Verapamil Hydrochloride Extended-Release Capsules, 300 mg | Phase 1 | Healthy |
| Amlodipine and Benazepril HCl Capsules 10 mg/20 mg | Phase 1 | Healhty |
| Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg | Phase 1 | Healthy |
| Finasteride Tablets 5 mg | Phase 1 | Healthy |